Aro Biotherapeutics

Focus: Aro Biotherapeutics is a publicly traded biotech company focused on protein scaffold and antisense oligonucleotide technologies for gene therapy applications. The company operates at an early clinical stage with a lean footprint and specialized technical focus.

Gene Therapy

Profile data last refreshed 8h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Aro Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Aro Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ABX1100

Late Onset Pompe Disease

Phase 1

Recent News · Aro Biotherapeutics(1)

Help build intelligence for Aro Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge protein scaffold and siRNA modalities in a focused therapeutic area (gene therapy for rare muscle disorders).
Recent positive Phase 1b data for ABX1100 in Late-Onset Pompe Disease signals pipeline momentum and validates core technology.
Public company status provides liquidity and potential for meaningful equity upside as pipeline progresses.

Watch Out For

Minimal hiring activity (only 1 active role across entire organization) indicates limited growth or expansion capacity.
Very early-stage pipeline with only 1 Phase 1 program and no marketed products means revenue and stability are years away.
Limited public financial data, employee count, and funding transparency make it difficult to assess long-term viability or cash runway.

Generated by Claude from Aro Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PipelineNews

Mar 17, 2026

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD) - Business Wire

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)  Business Wire

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Publications: 2 in PubMed

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease.

Molecular therapy : the journal of the American Society of Gene Therapy

2025

PMID:39604266

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet (London, England)

2022

PMID:35219377